Zymeworks Inc. Common Stock (ZYME) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zymeworks Inc. Common Stock (ZYME) has a cash flow conversion efficiency ratio of -0.098x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-31.41 Million) by net assets ($320.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Zymeworks Inc. Common Stock liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Zymeworks Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Zymeworks Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Zymeworks Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zymeworks Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Greif Bros Corporation
NYSE:GEF
|
0.038x |
|
Vimian Group AB
ST:VIMIAN
|
0.080x |
|
Vericel Corp Ord
NASDAQ:VCEL
|
0.042x |
|
Guangdong Baolihua New Energy Stock Co LTD
SHE:000690
|
0.014x |
|
Xinjiang Tianfu Energy Co Ltd
SHG:600509
|
0.047x |
|
Atrium Ljungberg AB (publ)
ST:ATRLJ-B
|
0.005x |
|
Stx Heavy Indu
KO:071970
|
0.064x |
|
Nanjing Hanrui Cobalt Co Ltd
SHE:300618
|
-0.086x |
Annual Cash Flow Conversion Efficiency for Zymeworks Inc. Common Stock (2014–2024)
The table below shows the annual cash flow conversion efficiency of Zymeworks Inc. Common Stock from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Zymeworks Inc. Common Stock.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $338.77 Million | $-110.04 Million | -0.325x | -27.63% |
| 2023-12-31 | $464.81 Million | $-118.30 Million | -0.255x | -187.06% |
| 2022-12-31 | $492.96 Million | $144.11 Million | 0.292x | +137.84% |
| 2021-12-31 | $249.09 Million | $-192.45 Million | -0.773x | -109.18% |
| 2020-12-31 | $409.92 Million | $-151.40 Million | -0.369x | -10.86% |
| 2019-12-31 | $245.68 Million | $-81.85 Million | -0.333x | -348.72% |
| 2018-12-31 | $180.49 Million | $24.18 Million | 0.134x | +7021.35% |
| 2017-12-31 | $116.43 Million | $219.00K | 0.002x | +100.05% |
| 2016-12-31 | $9.00 Million | $-35.25 Million | -3.915x | -222.11% |
| 2015-12-31 | $18.24 Million | $-22.17 Million | -1.216x | -589.12% |
| 2014-12-31 | $39.78 Million | $-7.02 Million | -0.176x | -- |
About Zymeworks Inc. Common Stock
Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. … Read more